Related Experiment Video

Updated: May 28, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Emerging antiangiogenic therapies for non-small-cell lung cancer

Collin Blakely1, Thierry Jahan

  • 1University of California, San Francisco, Box 1705, San Francisco, CA 94143-1705, USA.

Expert Review of Anticancer Therapy
|October 18, 2011
PubMed

Insights

Lung cancer is a leading cause of cancer deaths. New antiangiogenic therapies targeting vascular endothelial growth factor receptor (VEGFR) and other pathways are being investigated for advanced non-small-cell lung cancer (NSCLC).

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Lung cancer is the primary cause of cancer-related mortality globally.
  • Antiangiogenic therapy is a growing area of research for advanced non-small-cell lung cancer (NSCLC).
  • Bevacizumab is currently the sole approved antiangiogenic agent for NSCLC, demonstrating progression-free survival benefits and overall survival benefits in specific patient groups.

Purpose of the Study:

  • To review the current landscape of antiangiogenic therapies for advanced non-small-cell lung cancer (NSCLC).
  • To discuss emerging antiangiogenic strategies targeting multiple receptors and pathways.
  • To consider the integration of novel antiangiogenic agents into the existing NSCLC treatment paradigm.

Main Methods:

  • Review of Phase III clinical trial data, including the E4599 trial.
  • Analysis of ongoing studies evaluating new antiangiogenic agents.
  • Evaluation of therapeutic strategies targeting multiple angiogenic pathways (e.g., VEGFR, PDGF receptor) and mediators (e.g., integrins).

Main Results:

  • Bevacizumab has established efficacy in advanced nonsquamous NSCLC, showing progression-free and overall survival benefits.
  • Novel agents targeting multiple receptors (VEGFR-1, VEGFR-2) and pathways are under investigation.
  • Research is exploring agents that inhibit alternative angiogenesis mediators like integrins and established vasculature.

Conclusions:

  • The role of antiangiogenic therapy in NSCLC is expanding beyond bevacizumab.
  • New therapeutic strategies aim for broader inhibition of angiogenesis.
  • Future research will define the optimal placement of these novel agents within the NSCLC treatment framework.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...